Difficulty: Medium
Average Score: 85%
Practice
Which of the following nonopioid agents is an antidepressant with analgesic activity?
Correct answer
D
Rationale
The correct answer is D) Amitriptyline. Amitriptyline is a tricyclic antidepressant that possesses analgesic properties through multiple mechanisms, including inhibiting the reuptake of norepinephrine and serotonin. This dual action makes it effective in managing both depression and chronic pain conditions.
Option A) Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression and anxiety disorders, but it does not possess significant analgesic properties.
Option B) Moclobemide is a reversible inhibitor of monoamine oxidase-A (RIMA) used in the treatment of depression and social anxiety disorder, but it is not known for its analgesic effects.
Option C) Tranylcypramine is a monoamine oxidase inhibitor (MAOI) used for depression but does not have analgesic properties similar to amitriptyline.
Educationally, understanding the analgesic properties of certain antidepressants like amitriptyline is crucial for healthcare professionals when managing patients with comorbidities of depression and chronic pain. It highlights the importance of selecting medications that can address multiple symptoms effectively, leading to better patient outcomes and improved quality of life.
Option A) Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression and anxiety disorders, but it does not possess significant analgesic properties.
Option B) Moclobemide is a reversible inhibitor of monoamine oxidase-A (RIMA) used in the treatment of depression and social anxiety disorder, but it is not known for its analgesic effects.
Option C) Tranylcypramine is a monoamine oxidase inhibitor (MAOI) used for depression but does not have analgesic properties similar to amitriptyline.
Educationally, understanding the analgesic properties of certain antidepressants like amitriptyline is crucial for healthcare professionals when managing patients with comorbidities of depression and chronic pain. It highlights the importance of selecting medications that can address multiple symptoms effectively, leading to better patient outcomes and improved quality of life.